Compare UHS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | PTGX |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.5B |
| IPO Year | 1994 | 2016 |
| Metric | UHS | PTGX |
|---|---|---|
| Price | $173.09 | $157.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $216.36 | $108.23 |
| AVG Volume (30 Days) | ★ 883.7K | 470.6K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 11.63 | 2.35 |
| Revenue | ★ $17,364,829,000.00 | N/A |
| Revenue This Year | $7.67 | $874.25 |
| Revenue Next Year | $4.99 | N/A |
| P/E Ratio | ★ $14.66 | $67.50 |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $140.08 | $55.26 |
| 52 Week High | $246.33 | $158.95 |
| Indicator | UHS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 71.61 |
| Support Level | $173.79 | $94.48 |
| Resistance Level | $175.51 | N/A |
| Average True Range (ATR) | 5.38 | 5.13 |
| MACD | 0.10 | 1.22 |
| Stochastic Oscillator | 94.67 | 93.80 |
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.